Action IPSC CENTURY THERAPEUTICS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Century Therapeutics, Inc.

Actions

IPSC

US15673T1007

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 17/05/2024 		Varia. 5j. Varia. 1 janv.
3,01 USD -3,83 % Graphique intraday de Century Therapeutics, Inc. -3,83 % -9,34 %
10/05 Century Therapeutics présente des données précliniques soulignant les progrès de la technologie et des programmes de la plateforme Ipsc lors de la réunion annuelle de l'ASGCT en 2024 CI
09/05 Century Therapeutics, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024 CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Century Therapeutics Presents Preclinical Data Highlighting Advances in iPSC Platform Technology and Programs at 2024 ASGCT Annual Meeting
Century Therapeutics Presents Preclinical Data Highlighting Advances in iPSC Platform Technology and Programs at 2024 ASGCT Annual Meeting
Century Therapeutics Presents Preclinical Data Highlighting Advances in Ipsc Platform Technology and Programs At 2024 Asgct Annual Meeting
Century Therapeutics : Corporate Overview May 2024
Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
Century Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Century Therapeutics to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
Century Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
Century Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
Syncona agrees to sell stake in investee company for GBP7.4 million
Syncona to Sell Stake in Portfolio Company to Century Therapeutics
Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics
Century Therapeutics Announces Plans to Expand Clinical Development for Its Lead Program, CNTY-101
Century Therapeutics, Inc. acquired Clade Therapeutics, Inc. from Syncona Limited for $45 million..
Century Therapeutics, Inc. announced that it expects to receive $59.999982 million in funding from a group of investors
Century Therapeutics, Inc. agreed to acquire Clade Therapeutics, Inc. from Syncona Limited for $45 million.
Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research Annual Meeting
Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
Sector Update: Health Care Stocks Retreating Late Afternoon
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action IPSC
  4. Actualités Century Therapeutics, Inc.
  5. Autres langues